Cablivi (caplacizumab-yhdp) — Medica
Acquired thrombotic thrombocytopenic purpura (aTTP)
Initial criteria
- age ≥ 18 years
- Cablivi was initiated in the inpatient setting, in combination with plasma exchange therapy
- Patient is currently receiving at least one immunosuppressive therapy (e.g., systemic corticosteroids, rituximab or a rituximab product, cyclosporine, cyclophosphamide, mycophenolate mofetil, hydroxychloroquine, bortezomib)
- If the patient has previously received Cablivi, he/she has not had more than two recurrences of acquired thrombotic thrombocytopenic purpura while on Cablivi
- Prescribed by or in consultation with a hematologist
Approval duration
one course of treatment (up to 60 days following the last plasma exchange session)